Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) – Pipeline Review, H2 2017’, provides in depth analysis on Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Respiratory, Dermatology, Immunology and Ophthalmology under development targeting Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)

The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Allergan Plc

Boehringer Ingelheim GmbH

Brickell Biotech Inc

Idorsia Ltd

Merck & Co Inc

Novartis AG

Oxagen Ltd

Pulmagen Therapeutics LLP

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Overview 7

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 16

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Companies Involved in Therapeutics Development 17

Allergan Plc 17

Boehringer Ingelheim GmbH 17

Brickell Biotech Inc 18

Idorsia Ltd 18

Merck & Co Inc 19

Novartis AG 19

Oxagen Ltd 20

Pulmagen Therapeutics LLP 20

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Drug Profiles 21

ACT-774312 Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

ADC-3680 Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

ADC-7405 Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ADC-9971 Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

BBI-5000 Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

BI-1060469 Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

fevipiprant Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

MK-1029 Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

OC-2417 Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

setipiprant Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Timapiprant Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Dormant Products 38

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Discontinued Products 41

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Product Development Milestones 42

Featured News & Press Releases 42

Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma 42

Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma 43

Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers 43

Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis 45

Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 45

Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease 46

Oct 07, 2014: Atopix Therapeutics secures funding from SR One to advance development of CRTH2 antagonists in eosinophilic disease 47

Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study 47

Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma 47

Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis 48

May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis 48

Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders 49

May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis 49

Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma 50

Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 16

Pipeline by Allergan Plc, H2 2017 17

Pipeline by Boehringer Ingelheim GmbH, H2 2017 17

Pipeline by Brickell Biotech Inc, H2 2017 18

Pipeline by Idorsia Ltd, H2 2017 18

Pipeline by Merck & Co Inc, H2 2017 19

Pipeline by Novartis AG, H2 2017 19

Pipeline by Oxagen Ltd, H2 2017 20

Pipeline by Pulmagen Therapeutics LLP, H2 2017 20

Dormant Products, H2 2017 38

Dormant Products, H2 2017 (Contd..1), H2 2017 39

Dormant Products, H2 2017 (Contd..2), H2 2017 40

Discontinued Products, H2 2017 41

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports